New vs old fashioned oestradiol antagonists in mammary carcinoma: 'In vitro' and 'in vivo' pharmacological approaches

Pharmacological Research

Volumn 39, Issue 5, 1999, Pages 335-344

  De Cupis, Alessandra ^a   Schettini, Gennaro ^b   Favoni, Roberto E ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Antioestrogens; Breast cancer; Endocrinotherapy; Oestrogens

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; ANTIESTROGEN; ESTROGEN; TAMOXIFEN;

BREAST CARCINOMA; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

EID: 0033136349     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0437     Document Type: Article

References (62)

1. Ekena K, Katzenellenbogen JA, Katzenellenbogen BS. Determinants of ligand specificity of estrogen receptor-α: Estrogen versus androgen discrimination. J Biol Chem 1998; 273: 693-9.
2. Williams CL, Stancel GM. Estrogens and progestins. In: Goodman and Gilman's The Pharmacological BaSis of Therapeutics. Hardman, Limbrid, Molioff, Ruddon Gilman, eds. 1996; 57: 1411-40.
3. Folca PJ, Glascock RF, Irvine WT. Studies with tritium-labelled hexoestrol in advanced breast cancer. Lancet 1961; 7: 796-8.
4. Evans RM. The steroid and thyroid receptor family. Science 1988; 240: 889-95.
5. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 1996; 10: 119-31.
6. Parker MG. Action of 'pure' antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 1993; 26: 131-7.
7. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P. Functional domains of the human estrogen receptor. Cell 1987; 51: 941-51.
8. Lees JA, Fawell SE, Parker MG. Identification of two transactivation domains in the mouse oestrogen receptor. Nucleic Acid Res 1989; 17: 5477-88.
9. Catelli MG, Binart N, Jung TI, Renoir JM, Baulieu EE, Feramisco JR, Welch WJ. The common 90-Kd protein component of non-transformed '8S' steroid receptors is a heat shock protein. EMBO J 1985; 4: 3131-5.
10. Tora L, White J, Brou C, Tasset D, Webster N, Scheer E, Chambon P. The human estrogen receptor has two independent non acidic transcriptional activation function. Cell 1989; 59: 477-87.
11. Wakeling AE. Steroid antagonists as nuclear receptor blockers. Cancer Surv 1992; 14: 71-85.
12. De Cupis A, Favoni RE. Oestrogen/growth factor cross-talk in breast carcinoma: Specific target for novel antioestrogens. Trends Pharmacol Sci 1997; 18: 245-51.
13. Kuiper GJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925-30.
14. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: Suggestion for a new method of treatment with illustrative cases. Lancet 1896; 2: 104-7.
15. Harper MJK, Walpole AL. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethyllenes. Nature 1966; 212: 87.
16. Cole MP, Jones CTA, Todd IDH. A new antiestrogenic agent in late breast cancer: An early pre-clinical appraisal of ICI 46,474. Br J Cancer 1971; 25: 270-5.
17. Jaiyesimi IA, Buzdar AU, Dekcker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol 1995; 13: 513-29.
18. Favoni RE, De Cupis A. Steroidal and nonsteroidal oestrogen antagonists in breast cancer: Basic and clinical appraisal. Trends Pharmacol Sci 1998; 19: 406-15.
19. Draper MW, Flowers DE, Neild JA, Huster WJ, Zerbe RL. Antiestrogenic properties of raloxifene. Pharmacology 1995; 50: 209-17.
20. Scholl SM, Huff KK, Lippman ME. Antiestrogenic effects of LY117018 in MCF-7 cells. Endocrinology 1983; 113: 611-17.
21. Yang NM, Hardikar S. Estrogen receptor: Two ligand, two transcription pathways. J Bone Miner Res 1994; 9(Suppl. 1): S144.
22. Deschnes L. Droloxifene, a new antiestrogen in advanced breast cancer. Am J Clin Oncol 1991; 14(Suppl. 2): S52-5.
23. Eppenberg U, Wosikawski K, Kung W. Pharmacologic and biological properties of droloxifene, a new antiestrogen. Am J Clin Oncol 1991; 14(Suppl. 2): S5-14.
24. Gallo MA, Kaufman D. Antagonistic and agonistic effects of tamoxifen: Significance in human cancer. Semin Oncol 1997; 24(Suppl. 1): S71-80.
25. Ylikomi T, Bocquel MT, Berry M, Gronemeyer H, Chambon P. Cooperation of proto-signals for nuclear accumulation of estrogen and progesteron receptors. EMBO J 1992; 11: 1-14.
26. Sutherland RL, Watts CKW, Reunitz PC. Definition of two distinct mechanisms of action of antioestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the oestrogen receptor. Biochem Biophys Res Commun 1986; 140: 523-9.
27. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB. Inhibition of protein kinase C by tamoxifen. Cancer Res 1985; 45: 2462-5.
28. Berridge MJ, Irving RF. Inositol tryphosphate, a novel second messenger in cellular signal transduction. Nature 1984; 312: 315-21.
29. Rowland MG, Parr IB, MacCague R, Jarman M, Goddard PM. Variation of the inhibition of calmodulin dependent cyclic AMP phospho-diesterase among analogues of tamoxifen: Correlation with cytotoxicity. Biochem Pharmacol 1990; 40: 283-9.
30. Osborne CK, Arteaga CL. Autocrine and paracrine growth regulation of breast cancer: Clinical implications. Breast Cancer Res Treat 1990; 15: 3-11.
31. Cullen KJ, Yee D, Bates SE, Brunner N, Clarke RE, Dickson RE, Huff KK, Paik S, Rosen N, Valverius E, Zugmaier G, Lippman ME. Regulation of human breast cancer by secreted growth factors. Acta Oncol 1989; 28: 835-9.
32. Stewart AJ, Westley BR, May FEB. Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen. Br J Cancer 1992; 66: 640-8.
33. Bowler J, Lilley TJ, Pittam JD, Wakeling AE. Novel steroidal pure antioestrogen. Steroids 1989; 54: 71-99.
34. Wakeling AE, Dukes M, Bowler J. A potent specific antioestrogen with clinical potential. Cancer Res 1991; 51: 3867-73.
35. Wakeling AE. The future of novel pure steroidal antiestrogens in clinical breast cancer. Breast Cancer Res Treat 1993; 25: 1-9.
36. Thompson EW, Reich R, Shima TB, Albini A, Graf J, Martin G, Dickson RB, Lippman ME. Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antioestrogens. Cancer Res 1988; 48: 6764-8.
37. De Cupis A, Noonan D, Pirani P, Ferrera A, Clerico L, Favoni RE. Comparison between novel steroidal-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer derived cells. Br J Pharmacol 1995; 116: 2391-400.
38. Brunner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R. MCF-7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 1993; 53: 3229-32.
39. DeFriend DJ, Anderson E, Bell J, Wilks DP, West CML, Mansel RE, Howell A. Effects of 4-hydroxytamoxifen and a pure antioestrogen (ICI 182,780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer 1994; 70: 204-11.
40. Powels TJ. Efficacy of tamoxifen as treatment of breast cancer. Semin Oncol 1997; 24(Suppl. 1): S148-54.
41. Fisher B, Redmond C, Legault-Poisson S Dimitrov NV, Brown AM, Wickerham DL, Wolmark N, Margolese RG, Bowman D, Glass AG, Kardinal CG, Robidoux A, Jochimsen P, Cronin W, Deutsch M, Fischer ER, Myers DB, Hoehn J. Post-operative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990; 8: 1005-18.
42. Buzdar AU, Hortobagy GN. Tamoxifen and toremifene in breast cancer: Comparison of safety and efficacy. J Clin Oncol 1998; 16: 348-53.
43. Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwodo WR, Maillard JA, Jones SE, Vogel CL, Berris RF, shemano I, Schoenfelder J. Randomised comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995; 113: 2556-666.
44. Gradishar WJ, Jordan VC. Clinical potential of new antiestrogens. J Clin Oncol 1997; 15: 840-52.
45. Buzdar AU, Marcus C, Holmes F Phase II evaluation of LY156758 in metastatic breast cancer. Oncology 1988; 45: 344-5.
46. Howell A, DeFriend DJ, Robertson JFR, Blamey RW, Anderson L, Anderson E, Sutcliffe FA, Walton P. Pharmacokinetics, pharmacological and anti-tumor effects of the specific anti-oestrogen ICI 182,780 in women with advanced breast cancer. Br J Cancer 1996; 74: 300-28.
47. Vogel CL, Shemano I, Schoenfelder J, Gams RA, Green MR. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol 1993; 11: 345-50.
48. Sporn MB, Newton DL. Chemoprevention of cancer and retinoids. Fed Proc 1979; 38: 2528-34.
49. Sporn MB. Carcinogenesis and cancer: Different perspectives on the same disease. Cancer Res 1991; 51: 6215-18.
50. El-Bayoumy K. Evaluation of chemopreventive agents against breast cancer and proposed strategies for future clinical intervention trials. Carcinogenesis 1994; 15: 2395-420.
51. Early Breast Cancer Trialists Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 1988; 319: 1681-92.
52. Powels TJ. The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet 1992; 340: 1145-7.
53. Fentiman IS. Prospects for the prevention of breast cancer. Annu Rev Med 1992; 43: 181-94.
54. Nayfield SG, Karp JE, Ford LG, Dorr F, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991; 83: 1450-9.
55. Fugh-Berman A, Epstein S. Tamoxifen for breast cancer prevention: A cautionary review. Rev Endocr-Relat Cancer 1993; 43: 43-53.
56. Davidson NE. Tamoxifen-panacea or Pandora's box? N Engl J Med 1992; 326: 885-6.
57. Fisher B, Costantino JP, Wickerham LD, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidooooux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N, and other National Surgical Adjuvant Breast and Bowel Project Investigators. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project study. J Natl Cancer Inst 1998, 90: 1371-88.
58. Powels T, Eeles R, Ashley S, Eatson D, Chag J, Dowsett M, Tidy A, Viggers J, Davey J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98-101.
59. Veronesi U, Maissonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P. on the behalf of the Italian Tamoxifen Prevention Study. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 352: 93-7.
60. Cummings SR, Norton L, Eckert S et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Two year findings from the multiple outcomes of raloxifene trial. Proc Ann Meet Am Soc Clin Oncol 1998; 17: A3.
61. Moon RC, Mehta RG, Detrisac CJ. Retinoids as chemopreventive agents for breast cancer. Cancer Detec Prev 1992; 16: 73-9.
62. Noguchi M, Rose DP, Miyazaky I. Breast cancer chemoprevention: Clinical trials and research. Oncology 1996; 53: 175-81.